Skip to main content

Table 4 Clinical characteristics of COVID-19 patients with IL-6 receptor antagonists-associated DILI sourced from the FAERS database (2020q2 to 2021q4)

From: Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

Characteristics

Drug report, n (%)

TCZ

SAR

Patient age (year)

  

18–44

20 (10.42%)

0 (0.00%)

45–64

58 (30.21%)

3 (3.61%)

65–74

21 (10.94%)

0 (0.00%)

75–84

11 (5.73%)

0 (0.00%)

 ≥ 85

2 (1.04%)

0 (0.00%)

Unknown

80 (41.67%)

80 (96.39%)

Patient gender

  

Female

25 (13.02%)

1 (1.20%)

Male

89 (46.35%)

2 (2.41%)

Unknown

78 (40.63%)

80 (96.39%)

Reporter occupation

  

Consumer

2 (1.04%)

0 (0.00%)

Pharmacist

52 (27.08%)

1 (1.20%)

Physician

64 (33.33%)

82 (98.80%)

Unknown

74 (38.54%)

0 (0.00%)

Report time

  

2020Q2

13 (6.77%)

6 (7.23%)

2020Q3

29 (15.10%)

13 (15.66%)

2020Q4

23 (11.98%)

61 (73.49%)

2021Q1

20 (10.42%)

3 (3.61%)

2021Q2

53 (27.60%)

0 (0.00%)

2021Q3

25 (13.02%)

0 (0.00%)

2021Q4

29 (15.10%)

0 (0.00%)

Area

  

Africa

2 (1.04%)

0 (0.00%)

Asian

22 (11.46%)

0 (0.00%)

Europe

102 (53.13%)

13 (15.66%)

North America

53 (27.60%)

63 (75.90%)

South America

13 (6.77%)

7 (8.43%)

Outcomes

  

Congenital anomaly

0 (0.00%)

1 (1.22%)

Death

30 (17.14%)

30 (36.59%)

Disability

1 (0.57%)

1 (1.22%)

Hospitalization initial or prolonged

27 (15.43%)

37 (45.12%)

Life-threatening

6 (3.42%)

29 (35.37%)

Other serious (important medical event)

137 (78.29%)

54 (65.85%)

Required intervention to prevent permanent impairment

2 (1.14%)

0 (0.00%)